297 filings
Page 2 of 15
8-K
ijs9u9s
25 Apr 24
Departure of Directors or Certain Officers
4:01pm
S-3ASR
t7wqf
3 Apr 24
Automatic shelf registration
4:40pm
S-3ASR
3etjq huso
3 Apr 24
Automatic shelf registration
4:36pm
8-K
edhxf2
28 Mar 24
Immunome Reports Full-Year 2023 Financial Results and Provides Update on Recently Acquired Assets
4:04pm
8-K
ijav 9ey7ef142xws
26 Mar 24
Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala
8:05am
4
fagtpimtlb 6l7f
21 Feb 24
Immunome / Kinney Horn ownership change
9:10pm
3
w7lo67t
21 Feb 24
Immunome / Kinney Horn ownership change
9:07pm
8-K
9wrgqnl0swaf0nu 94
14 Feb 24
Other Events
4:11pm
424B5
xhxgxayk
14 Feb 24
Prospectus supplement for primary offering
4:09pm
424B5
2tr64wj5xlglzfn6qy
13 Feb 24
Prospectus supplement for primary offering
4:36pm
8-K
gxvfkhturxl or8
13 Feb 24
Results of Operations and Financial Condition
4:10pm
S-3ASR
dh469fd1s
13 Feb 24
Automatic shelf registration
4:04pm
SC 13G/A
18baogphcl5 s7y31qg
12 Feb 24
Immunome / Alpine Global Management ownership change
2:10pm
SC 13G
rld8sq31
9 Feb 24
Immunome / FMR ownership change
9:16am
8-K
niz3k 1qfp2yzt
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
S-8
u2cp j96ffdtojqsv9e
2 Feb 24
Registration of securities for employees
4:04pm
8-K
mwmdsd0iay
31 Jan 24
Departure of Directors or Certain Officers
9:18pm
4
8dejczdypo8h20c59d6i
31 Jan 24
Immunome / Max Rosett ownership change
8:53pm